Abstract
BACKGROUND.
Rhabdomyosarcoma (RMS) is a rare mesenchymal tumor with few treatment options after the failure of first‐line therapy. Understanding the expression of kinases and apoptotic molecules in RMS tumors may lead to elucidation of mechanisms of resistance to chemotherapy and development of new therapies.
METHODS.
Paraffin‐embedded tissue samples were collected from 105 RMS patients treated at the M. D. Anderson Cancer Center and examined for the immunohistochemical expression of kinases and apoptotic molecules deemed potential therapeutic targets. Clinicopathologic information was collected on all patients and analyzed for correlation with overall survival (OS).
RESULTS.
Of the 105 patients, 44 (42%) were female and 89 (85%) were older than 10 years of age. The 5‐year OS for this cohort was 24.7%, with inferior median OS in patients with genitourinary primary tumors and those with invasion through the deep fascial plane. Immunohistochemistry revealed Kit and c‐erb‐b2 to be present on < 10% of tumors but EGFR, PDGFR‐α, PDGFR‐β, Bcl‐2, and Bax were present in > 40% of tumors. Patients whose tumors expressed PDGFR‐α were found to have a shorter median OS by multivariate analysis (26 vs 266 months, P = .076). Conversely, patients whose tumors expressed Bax were found to have a longer OS (31 vs 19 months, P = .047).
CONCLUSIONS.
EGFR, PDGFR‐α, PDGFR‐β, Bcl‐2, and Bax are frequently expressed in human RMS tissue and may represent new therapeutic targets. Absence of PDGFR‐α and the presence of Bax are associated with a longer median OS in patients with RMS. Targeting these molecules may be a successful therapeutic strategy. Cancer 2007. © 2007 American Cancer Society.